Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines licensing

US FDA approves antibiotic combination with new beta-lactamase inhibitor

Intravenous combination antibacterial product Avycaz has been approved by the US Food and Drug Administration for the treatment of complicated infections.

US Food and Drug Administration has approved a new intravenous antibacterial product, Avycaz to treat intra-abdominal infections and urinary tract infections (pictured)

Source: Steve Gschmeissner / Science Photo Library

The US Food and Drug Administration has approved a new intravenous antibacterial product, Avycaz, to treat intra-abdominal infections and urinary tract infections (pictured)

The US Food and Drug Administration (FDA) has approved a new intravenous combination antibacterial product, Avycaz, for the treatment of complicated infections. It contains a third generation cephalosporin beta-lactam antibacterial ceftazidime and a new beta-lactamase inhibitor, avibactam.

The United States will be the first market for Avycaz, with an expected launch date in the second quarter of 2015. An application to the European Medicines Agency is expected to be made in the first quarter of 2015, says a spokesperson for AstraZeneca. It is jointly developing the product with Actavis, which has the distribution rights in North America.

The product is approved for the treatment of two conditions in adults (aged 18 years and over): complicated intra-abdominal infections, in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.

The product’s label stresses that to reduce the development of drug-resistant bacteria, Avycaz should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

The FDA fast-tracked Avycaz’s approval by designating it a qualified infectious disease product, which is given to antibacterial products that treat serious or life-threatening infections.

The most common cause of resistance to beta-lactam antibiotics, like ceftazidime, is due to the hydrolytic inactivation of the beta-lactam ring by bacterial beta-lactamases. More than 1,400 beta-lactamases have been identified, according to the FDA. Avibactam is a non-beta-lactam beta lactamase inhibitor with little antibacterial activity. Existing beta-lactamase inhibitors include clavulanic acid and tazobactam.

“The recent approval of ceftazidime-avibactam by the FDA adds another agent with activity against multidrug-resistant Gram-negative organisms to the potential armamentarium,” says Paul Wade, consultant pharmacist for infectious diseases at Guy’s & St. Thomas’ NHS Foundation Trust.

“Along with ceftolozane-tazobactam, approved by the FDA in 2014, this widens the range of agents with activity against extended-spectrum beta-lactamase (ESBL)-producing Gram-negative organisms.

“This comes at a time when concerns about rising carbapenem [a class of beta-lactam antibiotics] resistance and usage are at the forefront of national and international antimicrobial stewardship strategies and proposed quality measures in parts of the UK include reductions in carbapenem use in secondary care.”

Wade hopes these agents become available in the EU and UK soon so that “their carbapenem-sparing potential might be fully explored in practice”.

As well as protecting ceftazidime from ESBLs, Actavis says that the addition of avibactam to ceftazidime protects its breakdown by Klebsiella pneumoniae carpenemase and AmcP beta-lactamase producing pathogens.

The recommended dose of the product is 2.5g (2g ceftazidime and 0.5g avibactam) given every eight hours by intravenous infusion over two hours for 5 to 14 days. The most common side effects include vomiting, nausea, constipation and anxiety. The FDA says decreased efficacy, seizures and other neurological events were seen in patients with poor renal function.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068039

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.